HRP20050436B1 - Kinolinil-pirolpirazoli - Google Patents

Kinolinil-pirolpirazoli

Info

Publication number
HRP20050436B1
HRP20050436B1 HRP20050436AA HRP20050436A HRP20050436B1 HR P20050436 B1 HRP20050436 B1 HR P20050436B1 HR P20050436A A HRP20050436A A HR P20050436AA HR P20050436 A HRP20050436 A HR P20050436A HR P20050436 B1 HRP20050436 B1 HR P20050436B1
Authority
HR
Croatia
Prior art keywords
pirolpyrzole
quinolinyl
compound
patient
formula
Prior art date
Application number
HRP20050436AA
Other languages
English (en)
Croatian (hr)
Inventor
Douglas Wade Beight
Jason Scott Sawyer
Jonathan Michael Yingling
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20050436A2 publication Critical patent/HRP20050436A2/xx
Publication of HRP20050436B1 publication Critical patent/HRP20050436B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20050436AA 2002-11-22 2003-11-10 Kinolinil-pirolpirazoli HRP20050436B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42889302P 2002-11-22 2002-11-22
PCT/US2003/032747 WO2004048382A1 (en) 2002-11-22 2003-11-10 Quinolinyl-pyrrolopyrazoles

Publications (2)

Publication Number Publication Date
HRP20050436A2 HRP20050436A2 (en) 2005-10-31
HRP20050436B1 true HRP20050436B1 (hr) 2013-11-08

Family

ID=32393478

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050436AA HRP20050436B1 (hr) 2002-11-22 2003-11-10 Kinolinil-pirolpirazoli

Country Status (28)

Country Link
US (2) US7265225B2 (enExample)
EP (1) EP1565471B1 (enExample)
JP (1) JP4542906B2 (enExample)
KR (1) KR101057282B1 (enExample)
CN (1) CN100345852C (enExample)
AT (1) ATE341550T1 (enExample)
AU (1) AU2003291643B2 (enExample)
BR (1) BR0315337A (enExample)
CA (1) CA2501322C (enExample)
CO (1) CO5570677A2 (enExample)
CR (1) CR7830A (enExample)
CY (1) CY1106283T1 (enExample)
DE (1) DE60308893T2 (enExample)
DK (1) DK1565471T3 (enExample)
EA (1) EA008387B1 (enExample)
EC (1) ECSP055807A (enExample)
EG (1) EG25822A (enExample)
ES (1) ES2273046T3 (enExample)
HR (1) HRP20050436B1 (enExample)
IL (1) IL168190A (enExample)
MX (1) MXPA05005432A (enExample)
NO (1) NO331403B1 (enExample)
NZ (1) NZ538942A (enExample)
PL (1) PL227840B1 (enExample)
PT (1) PT1565471E (enExample)
UA (1) UA80571C2 (enExample)
WO (1) WO2004048382A1 (enExample)
ZA (1) ZA200503121B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US7405299B2 (en) * 2002-11-27 2008-07-29 Eli Lilly And Company Compounds as pharmaceutical agents
CA2616196C (en) * 2005-07-22 2012-08-21 Eli Lilly And Company A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
CN101553254A (zh) 2006-10-03 2009-10-07 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
EP2527345B1 (en) * 2006-10-16 2015-12-16 Thesan Pharmaceuticals, Inc. Therapeutic pyrazolyl thienopyridines
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
CN105007939B (zh) 2012-10-05 2018-10-19 卡德门企业有限公司 人抗vegfr-2/kdr抗体
EP2917365B1 (en) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Methods and kits for the prognosis of colorectal cancer
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) * 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
EP3827010B1 (en) 2018-07-23 2025-08-27 Brise Pharmaceuticals Co., Ltd. Bisphosphonate drug conjugates
SG11202103457PA (en) 2018-12-27 2021-05-28 Nexys Therapeutics Inc (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531901A2 (en) * 1991-09-09 1993-03-17 Fujisawa Pharmaceutical Co., Ltd. Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity
WO2002094833A1 (en) * 2001-05-24 2002-11-28 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267830T1 (de) * 1999-08-27 2004-06-15 Abbott Lab Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
EP1567528A1 (en) 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531901A2 (en) * 1991-09-09 1993-03-17 Fujisawa Pharmaceutical Co., Ltd. Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity
WO2002094833A1 (en) * 2001-05-24 2002-11-28 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
US20080027102A1 (en) 2008-01-31
NO20053045L (no) 2005-06-21
EA200500859A1 (ru) 2005-10-27
US7834029B2 (en) 2010-11-16
WO2004048382A1 (en) 2004-06-10
CR7830A (es) 2005-06-20
KR20050083945A (ko) 2005-08-26
US20060040983A1 (en) 2006-02-23
DE60308893D1 (de) 2006-11-16
JP4542906B2 (ja) 2010-09-15
ECSP055807A (es) 2005-08-11
DE60308893T2 (de) 2007-03-15
UA80571C2 (en) 2007-10-10
CN1714090A (zh) 2005-12-28
CA2501322C (en) 2011-05-10
NZ538942A (en) 2007-01-26
PL376797A1 (pl) 2006-01-09
JP2006514012A (ja) 2006-04-27
EG25822A (en) 2012-08-23
DK1565471T3 (da) 2007-02-05
CN100345852C (zh) 2007-10-31
CO5570677A2 (es) 2005-10-31
KR101057282B1 (ko) 2011-08-16
EP1565471B1 (en) 2006-10-04
EP1565471A1 (en) 2005-08-24
ES2273046T3 (es) 2007-05-01
US7265225B2 (en) 2007-09-04
AU2003291643B2 (en) 2010-05-13
CA2501322A1 (en) 2004-06-10
ZA200503121B (en) 2006-07-26
MXPA05005432A (es) 2005-08-03
NO331403B1 (no) 2011-12-19
HK1081948A1 (en) 2006-05-26
PL227840B1 (pl) 2018-01-31
HRP20050436A2 (en) 2005-10-31
AU2003291643A1 (en) 2004-06-18
BR0315337A (pt) 2005-08-16
PT1565471E (pt) 2007-01-31
EA008387B1 (ru) 2007-04-27
IL168190A (en) 2011-01-31
CY1106283T1 (el) 2011-10-12
ATE341550T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
DK1565471T3 (da) Quionolinylpyrazoler
SG2013013339A (en) N3 alkylated benzimidazole derivatives as mek inhibitors
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2003077855A3 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
SG149033A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
GEP20053659B (en) Aryl And Heteroaryl Urea CHK1 Inhibitors for Use as Radiosensitizers and Chamosensitizers
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
SE9900961D0 (sv) Novel compounds
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
SE0104248D0 (sv) Method of treatment
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
BR0311333A (pt) ésteres na posição 20 de camptotecinas
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
SE0301884D0 (sv) New use III
NO20051261L (no) Morfin-6-glukuronidsalt
CY1112457T1 (el) Χρωμανο- και θειοxρωμανο-3-υλο-1,3-διυδρο-ιμιδαζολια ως αναστολεις της ντοπαμινο-β-υδροξυλασης, και μεθοδοι παρασκευης αυτων
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
ATE319689T1 (de) Naphthamidin-urokinasinhibitoren
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
RU2002128559A (ru) Способ реабилитации женщин после оперативного лечения трубного бесплодия

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20171109

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20181110